SUMMARY Antibodies were raised against a newly synthesized analog (CP57.609) of the o,-selective antagonist prazosin, and against the a.-selective antagonist, yohimbine, by Immunization of rabbits with antigens prepared by covalent linkage of these Uganda to albumin. Competitive Inhibition of [ a H]prazosln binding to anti-CP57,609 antiserum by a variety of nnlabeled Uganda revealed a spectrum of antibody specificity, with a r selective agents competing more potently than a,-seiectiTe llgands. In contrast, a,-selective ligands competed more potently with the binding of ['H]yofaimbine to the anti-yohlmbine antiserum than a^-selective agents. These respective antisera were subjected to affinity fractionation on a CP57,609-or yohimbine-Sepharose 4B resin. Fractions from the CP57,609 resin were eluted successively with phentolamine (10~'M), prazosin (10 4 M), and guanidine (5M), and from the yohimbine resin with prazosin (10^M), yohimbine (HMM), and guanldlne (SM). The binding profiles of these fractions differed, and in certain fractions the relative order of potency of adrenergic agents was almost identical to that observed with membrane a-adrenergic receptors. Moreover, using these eluted fractions as immunogens, antisera have been obtained which, in the initial bleeds, already possess antiidiotypic activity. These findings therefore suggest that affinity fractionation of antibodies raised against a r and a t -selective antagonists may provide useful analogs for the further study of the ligand recognition properties of a-adrenergic receptors. Additionally, it is probable that antiidiotypic antisera will be developed which will recognize the a-adrenergic binding sites. A S with the /?-adrenergic system, the binding of pharmacologically active agents to a membrane receptor is the requisite first step in aadrenergic modulation of cellular processes. On the basis of pharmacologic and radioligand binding studies, these receptors have been identified in a number of tissues 1 and subclassified according to their relative affinities for a variety of a-adrenergic agonists and antagonists into a x -and at-subtypes. J However, little is known about the molecular interaction of aadrenergic agents with these membrane-binding sites, as the purification of the receptor proteins and their structural characterization have not been performed. As an alternative indirect approach to studies of the /8-adrenergic receptor, we have developed /8-antagonistspecific antiserum and demonstrated that its component antibodies can be used as probes to study the ligand recognition properties of the /J-adrenergic receptor. 8 In the present paper, a similar approach has been applied to studies of the recognition properties of a-adrenergic receptors by the development and affinity fractionation of a,-and a a -selective antagonist-specific antibodies.
A S with the /?-adrenergic system, the binding of pharmacologically active agents to a membrane receptor is the requisite first step in aadrenergic modulation of cellular processes. On the basis of pharmacologic and radioligand binding studies, these receptors have been identified in a number of tissues 1 and subclassified according to their relative affinities for a variety of a-adrenergic agonists and antagonists into a x -and at-subtypes. J However, little is known about the molecular interaction of aadrenergic agents with these membrane-binding sites, as the purification of the receptor proteins and their structural characterization have not been performed.
As an alternative indirect approach to studies of the /8-adrenergic receptor, we have developed /8-antagonistspecific antiserum and demonstrated that its component antibodies can be used as probes to study the ligand recognition properties of the /J-adrenergic receptor. 8 In the present paper, a similar approach has been applied to studies of the recognition properties of a-adrenergic receptors by the development and affinity fractionation of a,-and a a -selective antagonist-specific antibodies.
Methods

Materials
PH]Prazosin (specific activity 28 Ci/mmoles) was obtained from Amersham (Arlington Heights, Illinois) and [*H]yohimbine (80 Ci/mmoles) from New England Nuclear (Boston, Massachusetts). Guanidine, (-)epinephrine, yohimbine, corynanthine, and human serum albumin were obtained from Sigma (St. Louis, Missouri); phentolamine from Ciba-Geigy (Summit, New Jersey); agarose (Sepharose 4B) from Pharmacia (Piscataway, New Jersey); and pyro- catechol from Aldrich (Milwaukee, Wisconsin). The following were gifts: prazosin and trimazosin (Pfizer, Groton, Connecticut); BL 5111A (4-amino-6,7-dimethoxy-2-[4-{5-methylthio-l,3,4-oxidiazole-2-carbonyl)-piperazin-l-yl-]quinazoline hydrochloride) (Bristol, Syracuse, New York); rauwolscine (Roth, Karlsriihe, West Germany), and phenoxybenzamine (Smith, Kline and French, Philadelphia, Pennsylvania).
Preparation of the Antigens and Antisera
The synthesis of CP57.609 (2-[4-succinoyl-piperazin-l-yl]-4-amino-6,7-dimethoxyquinazoline) will be described fully in a separate communication. The a,-selective antagonist, yohimbine, was demethylated by alkaline hydrolysis to produce an analog with a free carboxy terminus. Demethylation was confirmed by thin-layer chromatography. The yohimbine analog was then coupled to albumin, as described previously for CP57.6O9. 4 The prazosin analog, CP57.6O9, has a K D of 270 nM for the arreceptor of liver as assessed by competitive inhibition analysis employing ['HJprazosin. Less than 20% inhibition of [*H]yohimbine binding to the a,-receptor in these liver membranes was effected at a CP57.609 concentration of 100 (iM. Thus, this prazosin analog demonstrates a 1000-fold greater selectivity for the o^-receptor. In contrast, demethylated yohimbine produced a 50% inhibition of ['HJyohimbine binding to the a a -receptor at a concentration of 1 /xM while effecting an approximate 20% inhibition of ['HJprazosin binding to the arreceptor at a concentration of 100 fiM. It therefore demonstrates a 500-fold greater selectivity for the ai-receptor. Albino rabbits were immunized with the ligand-protein complexes and antisera harvested as described previously for the development of /^-antagonist-specific antibodies. 8 Anti-CP57,609 and Anti-Yohimbine Antibody Binding Assays
The ligand affinities of the antisera were determined by a double antibody precipitation competitive binding assay as previously described' using ["HJprazosin (2-10nM) and ['Hjyohimbine (2-10nM) as the radioligands for the anti-CP57,6O9 and anti-yohimbine antisera, respectively.
Affinity Fractionation of the Antisera
The CP57,6O9-substituted resin was prepared as previously described, 4 and a similar procedure was used to develop a yohimbine-Sepharose 4B resin. Affinity fractionation of the antisera was achieved by incubating 10-20 ml with 2.5-5.0 ml of the respective substituted resin for 30 minutes at room temperature. After centrifugation, the supernatant was removed and the resin washed with 5 X 50 ml-aliquots of buffer (50 mM Tris, pH 7.4). Elution from the CP57.609 resin was obtained by incubating the resin successively with phentolamine (,10~'M), prazosin (10~4M) and guanidine (5M). Elution from the yohimbine resin was similarly obtained using prazosin (10~4M), yohimbine (lO^M), and guanidine (5 M). Desorption of prazosin was achieved by dialysis (3 X 8 hr X 41) against 0.1 M acetic acid and then 50 mM Tris, pH 7.4 (3 X 8 hr X 41), whereas only the latter dialysate was used to remove the other eluting agents.
Results
As shown in figure 1 , high titer antisera were elicited from rabbits immunized with either the CP57.609-or yohimbine-albumin complex. These antibodies not only bound the ligands but also structurally related analogs, e.g., prazosin, BL 5111A, and trimazosin (anti-CP57,6O9 antiserum); yohimbine and rauwolscine (anti-yohimbine antiserum) (table 1). A lower affinity interaction was observed with structurally distinct a-adrenergic ligands. However, the relative order of potency of the unlabeled ligands determined from their ability to competitively inhibit ['HJprazosin binding by the anti-CP57,609 antiserum or ['Hjyohimbine binding by the anti-yohimbine antiserum was similar to that observed at a r or a,-receptors, respectively, in pharmacologic and radioligand binding studies." Thus, with the anti-CP57,6O9 antisera, the ^-selective antagonist, prazosin, was more potent than the nonselective antagonist, 
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phenoxybenzamine, which in turn was more potent than the a a -selective antagonist, yohimbine; whereas pyrocatechol and the /3-antagonist, (-)-alprenolol, did not inhibit antibody binding of the radioligand ( fig. 2 ). By contrast, the relative order of potency observed with the anti-yohimbine antisera, yohimbine > phenoxybenzamine > prazosin » (-)alprenolol = pyrocatechol, was similar to that of a,-membrane receptors. Despite this general agreement with the potency order of a-adrenergic ligands, at a-adrenergic receptors, the antisera affinity for certain ligands was not appropriate. Thus, with the anti-CP57,609 antiserum the nonselective antagonist, phentolamine, was less potent than yohimbine, while high concentrations of the a-agonist, (-)-epinephrine, failed to inhibit high affinity ['HJprazosin binding. Similarly, a lower affinity interaction by the anti-yohimbine antiserum was observed with phentolamine than with prazosin.
Since the immune response to a haptenic antigen normally comprises a broad class of antibodies with varying binding affinity and specificity ,'• T affinity fractionation of antiligand antisera might be expected to yield binding site subpopulations that would identify distinct and possibly identical structure-function relationships to that observed with the a-adrenergic receptor. To this end, ligand-substituted resins were synthesized and the antisera affinity fractionated. Elution of the component antibodies was then effected biospecifically with structurally related or distinct ligands and nonspecifically by protein denaturation with guanidine. 
The IC30 was determined from competitive inhibition studies as described-in figure 2 . Results shown are the means of three separate determinations with each ligand. Dashea indicate not tested.
Virtually no radioligand binding was detectable in the fall-through fractions, suggesting almost complete extraction of the antibodies by the affinity resins ( fig.  3 ). Binding capacity was enhanced, however, in all of the column-retarded fractions and this enhancement 
FIGURE 2. Binding profiles of unfractionated anti-CP57,609 (A) and anti-yohimbine (B) antisera. Competitive inhibition of f HJprazosin or fHJyohimbine binding by the various ligands shown was assessed using the anli-CP57,609 (1:1000) or anti-yohimbine (I'-IOO) antiserum, respectively. Incubations were performed with 50 id of the appropriate dilution of serum, 25 nl radioligand (2 X 10~'M, final dilution) and 25 f i l of buffer or 25 ill of various concentrations of unlabeled ligand. Bound radioactivity was determined as described previously* and corrected for nonspecific binding to the preimmune serum.
11-186 FIGURE 3. Binding capacity of unfractionated antiserum, preimmune serum, fallthrough fraction, and various eluted fractions of the anti-CP57,609 antiserum (A) and antiyohimbine antiserum (B). Incubations were performed as described in the legend to figure I using 10~"M (final dilution) of each radioligand. Binding not inhibitable by 10'*M prazosin (A) or yohimbine (Bj was used as the blank and subtracted from the bound radioactivity.
was most marked in those fractions eluted biospecifically with agents structurally related to the resin substituents. Different binding profiles were observed with the various eluted fractions (fig. 4 ). For example, phentolamine and the a-adrenergic agonist, (-)-epinephrine, which interacted, although with low affinity, with the anti-yohimbine antiserum, did not inhibit the binding of [ s H]yohimbine by the yohimbineand guanidine-eluted fractions. Thus, the spectrum of 
FIGURE 4. Comparison of the binding profile of the phentolamine-(B), prazosin-(C), and guanidine-eluted (D) fractions with that of the unfractionated anti-CP57,609 antiserum (l'-1000)(A). See legend to figure 2 for details.
ligand recognition by these latter elutions was restricted by removal of these low-affinity antibodies by the preceding prazosin elution. In contrast, the spectrum of ligand recognition by the anti-CP57,609 antiserum was enhanced by affinity fractionation of the component antibodies. Thus, agonist binding, which was not detectable with the native antiserum, became apparent in the prazosin-and guanidine-eluted fractions. This phenomenon most likely reflects the separation of a subclass of binding sites with an inherently lower affinity for prazosin, yet possessing a complementary region that recognizes an epitope common to both agonists and antagonists. Moreover, these eluted fractions demonstrate a specificity for aadrenergic ligands that more closely mimic the a,-adrenergic receptor: prazosin > phentolamine > yohimbine > (-)-epinephrine. 8 This property of specificity may thus be inherent to those fractions capable of recognizing a-agonists, albeit with low affinity.
Using the above eluted fractions as immunogens, we have obtained antisera which, in the initial bleeds, already possess potent antiidiotypic activity (table 2) .
Discussion
It is well recognized that the requisite properties of cellular receptors include reversible high-affinity binding, reflecting the biological potency of the native ligands and their structural analogs.
9 -10 Although aadrenergic receptors in a number of tissues have been characterized with respect to their ligand-binding profiles, the structural properties of their binding sites and thus critical questions concerning their molecular interaction with catecholamines. remain undetermined. Fortuitously, several of the requisite characteristics of true receptor-binding sites are shared by the antigen-combining site of immunoglobulins. For this reason, we have previously employed the elicited immune response to gain insights into the recognition properties of the /?-adrenergic receptor. 3 In those ALPHA-ADRENERGIC ANTAGONIST ANTIBODIES/GraAow et al. studies, a number of different antibodies resulted from the use of a /8-antagonist-protein conjugate as the antigenic determinant. Some of these antibodies recognized structural aspects of the hapten that were irrelevant to its biological activity, whereas others detected features shared by the antigen as well as by other /?-adrenergic agonists and antagonists. By affinity fraction of the /3-antagonist-specific antiserum and elution with specific ligands, a class of antibodies was selected that possessed close similarities in their recognition properties to that of the /3-adrenergic receptor.
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In the present study, we have adopted a similar approach to gain insights into the molecular interactions of adrenergic ligands with a,-and a a -adrenergic receptors. To this end, an analog of the a^selective antagonist, prazosin, was synthesized which could be readily coupled via an amide linkage to a protein carrier or a resin. Similarly, by chemical modification of the a,-selective antagonist, yohimbine, a derivative was obtained with a reactive carboxy moiety. Immunization with the ligand-protein complexes resulted in the development of antisera that recognized both the haptens and their parent analogs with high affinity. Moreover, their binding profiles for a variety of adrenergic ligands were, in part, similar to those of the respective a-adrenergic receptor subtypes.
To gain additional insights into the functional relationship of structural diversity to binding, the antisera were fractionated by affinity chromatography. Elution of the adsorbed fractions of the anti-yohimbine antiserum with a ligand structurally distinct from the resin substituent restricted the binding profiles of the subsequent yohimbine-and guanidine-eluted fractions. However, the elution of the resin-retard fractions of the anti-CP57,6O9 antiserum with phentolamine resulted in the emergence of a class of antibodies with agonist specificity, in the subsequent prazosin-eluted fraction. The binding profile of the latter fraction was also altered to be closely similar to that of the aj-adrenergic receptor. It would appear, then, that when affinity chromatography is employed to select a fraction that recognizes agonists, a complementarity is observed such that this fraction possesses appropriate specificity as well. Thus, a corollary may exist such that either of these functions defines a three-dimensional site with ligand binding properties characteristic of the a r adrenergic receptor.
Isolation of the individual antibody molecules of interest should thus permit intensive investigation into the molecular nature of a-adrenergic ligand binding to the antibody combining site. Furthermore, the affinity-fractionated rabbit antisera can be used as antigens for the production of antiidiotypic antibodies, which can be predicted to interact with a similarly structured binding site on the a-adrenergic receptor itself. Such antiidiotypic antibodies that recognize and inhibit ligand binding to the /3-adrenergic receptor, as well as inhibiting receptor-mediated cyclase activation, have already been developed by use of /9-antagonist-specific antibodies as immunogens. 11 It is probable, therefore, that these a-antagonist-specific antibodies, which have ligand recognition properties similar to a-adrenergic receptors, will yield antiidiotypic antibodies with high affinity for the biological receptor. Indeed, antisera with marked antiidiotypic activity have already been raised (table 2) , although cross reactivity with the a-adrenergic receptor itself has not yet been observed.
